BREAKING: @US_FDA clears the first test to detect and monitor minimal residual disease in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (ALL). https://t.co/hEd0VB1o3r. #mmsm#leusm#NGS#MRD#immunosequencing